Abstract: Objective: To evaluate the efficacy and safety of docetaxel (Wanle) and docetaxel (Wanle) plus cisplatin regimen in patients with breast cancer and non-small cell lung cancer. Methods: 1) Single agent regimen: patients of breast cancer (group A) and NSCLC (group B)were treated with docetaxel 75mg/m² in the first day, and the schedule was repeated every 21 days. 2) Combination regimen: patients with breast cancer were randomly assigned to receive docetaxel (Wanle) 70mg/m² iv + cisplatin 80mg/m² (group C) treatment or taxotere 70mg/m² iv + cisplatin 80mg/m² iv treatment (group D), the schedule was repeated every 21 days. Patients with NSCLC were also randomly assigned to regimens of docetaxel (Wanle)+cisplatin (group E) and Taxotere + cisplatin (group F). Results: A total of 138 of the 147 patients were evaluative for efficacy and 141 of the patients were evaluative for side effects. Overall response rate of group A, B, C, D, E , F was 21.7%, 6.1%, 60.0%, 35%, 23.8% and 28.6%, respectively. The major side effects were myelosuppression, neutropenia, nausea, vomiting and alopecia. Conclusion: The docetaxel (Wanle) is effective and well tolerated in the treatment of advanced NSCLC and breast cancer. Efficacy and side effect of docetaxel (Wanle) are similar to the imported Taxotere.